EUVIMEDEUVIMED entdecken
Crossref

AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B ‐Associated DNA Repair in Bladder Cancer

Zehua Liu, Bolin Jia, Zhao Zhai, Fan Wu, Bin Jia, Zhan Yang, Yong Zhang iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202500423r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Zehua Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Deoxycytidine, Cisplatin, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), The Taishan Scholars Program of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of gemcitabine and cisplatin serves as a cornerstone in bladder cancer (BC) treatment, yet chemotherapy resistance continues to pose a significant challenge. This study utilizes a novel BC organoid model integrated with drug sensitivity assays to uncover the mechanisms underlying resistance and identify potential therapeutic targets. Our findings reveal that AP1M2 expression is markedly upregulated in gemcitabine‐ and cisplatin‐resistant BC cells and tissues. Elevated AP1M2 levels contribute to enhanced chemotherapy resistance and tumor cell proliferation by facilitating the DNA damage response and increasing RAD54B expression. Mechanistically, AP1M2 interacts with the RNA‐binding protein PUM1 to stabilize RAD54B mRNA, thereby supporting DNA repair and survival under chemotherapeutic stress. Notably, inhibition of AP1M2/PUM1‐mediated RAD54B expression sensitized BC xenografts to gemcitabine‐cisplatin treatment in vivo. These findings unveil a novel mechanism of chemotherapy resistance in BC and highlight the AP1M2/PUM1/RAD54B pathway as a promising therapeutic target to counter resistance and enhance treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDeoxycytidineCisplatinDrug Resistance, NeoplasmDNA RepairNuclear ProteinsDNA HelicasesHumansGemcitabineAnimalsMiceCell Line, TumorMice, NudeRNA-Binding ProteinsXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticCell ProliferationFemale

Stichwörter der Autor:innen

AP1M2DNA repairbladder cancerchemoresistancegemcitabine‐cisplatin

Substanzen

DeoxycytidineGemcitabineCisplatinRAD54B protein, humanNuclear ProteinsDNA HelicasesRNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing, China.
  • Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.

ORCID-Profile: Yong Zhang

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • The Taishan Scholars Program of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Liu, Z., Jia, B., Zhai, Z., Wu, F., Jia, B., Yang, Z., & Zhang, Y. (2025). AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B ‐Associated DNA Repair in Bladder Cancer. The FASEB Journal. https://doi.org/10.1096/fj.202500423r

Vancouver

Liu Z, Jia B, Zhai Z, Wu F, Jia B, Yang Z, et al. AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B ‐Associated DNA Repair in Bladder Cancer. The FASEB Journal. 2025. doi:10.1096/fj.202500423r

BibTeX
@article{Liu2025,
  author = {Liu, Zehua and Jia, Bolin and Zhai, Zhao and Wu, Fan and Jia, Bin and Yang, Zhan and Zhang, Yong},
  title = {AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B ‐Associated DNA Repair in Bladder Cancer},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202500423r}
}
Kostenlos starten →